The Inflation Reduction Act of 2022 will strengthen Medicare’s prescription drug coverage by imposing a hard $2,000 cap on out-of-pocket spending, providing critical relief for many beneficiaries.
The 2025 Medicare changes mean many beneficiaries need to review their coverage options during the current enrollment period, as insurance plans may elevate premiums and change covered drugs.
While traditional Medicare Part A and B with Medigap policies do not require reevaluation, it is crucial to reassess stand-alone Part D plans and Medicare Advantage policies.
Beneficiaries taking costly drugs for conditions such as cancer will benefit greatly from the new drug coverage measures, which will enhance predictability in healthcare spending.
Collection
[
|
...
]